Cancer - Kidney(구연) (E-088) 신장암에서 ginsenoside 와 sunitinib 의 복합 치료 효과 ¹한양대학교 의과대학 비뇨의학교실 ²한양대학교 의생명공학전문대학원 임상의과학과 황현지¹·², 이지영¹, 홍성휘¹, 장은비¹·², 문홍상¹, 윤영은¹, 박성열¹* Anti-tumor effects of ginsenoside Rg3 and Rh2, are currently being studied. But, there are lack of studies on renal cell carcinoma (RCC). Therefore, in this study, we investigated the effect of ginsenoside Rg3 and Rh2 on RCC and evaluate the effect of co-treatment with sunitinib. Cell proliferation was measured by MTT assay kit. RCC cell line, A498 and 786-O cells were treated with Rg3, Rh2 and sunitinib 10uM for 24hr. Cell cycle was studied by staining with 50ug/ml propidium iodide (PI) and analyzed by flow cytometry. Apoptosis was quantified by Annexin-V staining. Cells were reacted with Annexin-V-fluorescein and PI for 10min at RT following manufacturer’s instructions and then, cells were analyzed. The percentage of death cells corresponds to PI-positive cells and Annexin V/PI double positive cells. Ginsenoside Rg3 and Rh2 suppressed cell growth in both cell lines. Co-treatment of ginsenoside and sunitinib enhanced cell growth suppression. An increase of apoptosis was found in both cell lines when treated with Rg3 and Rh2. In order to confirm the cause of cell death, a cell cycle arrest experiment was conducted. When ginsenoside Rg3 and Rh2 were treated simultaneously with Sunitinib, cell cycle was arrested in G2/M phases. Ginsenoside Rg3 and Rh2 showed anti-tumor effect in renal cell carcinoma. Ginsenoside Rg3 and Rh2 enhanced anti-proliferation effect of sunitinib by cell cycle arrest. Ginsenoside Rg3 and Rh2 may be a new strategy for the treatment of RCC in combination with sunitinib. keywords : Ginsenoside Rg3, Ginsenoside Rh2, Sunitinib, Renal cancer, kidney cancer